Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

July 31, 1999

Primary Completion Date

January 31, 2001

Study Completion Date

January 31, 2001

Conditions
HIV Infections
Interventions
DRUG

Lamivudine/Zidovudine

DRUG

Nelfinavir mesylate

DRUG

Stavudine

DRUG

Didanosine

Trial Locations (23)

15213

Anderson Clinical Research, Pittsburgh

23666

Hampton Roads Med Specialists, Hampton

32960

Dr Gerald Pierone Jr, Vero Beach

33023

County Line Med CtrInc, Pembrook

33308

Med Alternatives, Fort Lauderdale

35203

Sorra Research Ctr / Med Forum, Birmingham

48202

Henry Ford Hosp, Detroit

60612

The CORE Ctr, Chicago

75235

Univ of Texas Southwestern Med Ctr of Dallas, Dallas

77004

Gathe, Joseph, M.D., Houston

77006

Montrose Clinic, Houston

85016

Body Positive, Phoenix

94115

San Francisco Gen Hosp, San Francisco

432101228

Ohio State Univ Hosp Clinic, Columbus

462025250

Indiana Univ Med Ctr, Indianapolis

672143124

Univ of Kansas School of Medicine, Wichita

900276069

AIDS Healthcare Foundation, Los Angeles

03756

Dartmouth-Hitchcock Med Ctr, Lebanon

07103

NJCRI, Newark

08876

Infectious Disease Assoc of Central Jersey, Somerville

Unknown

Clinique Medicale du Quartier Latin, Montreal

Clinique Medicale L'Actuele, Montreal

Dr Roger P Leblanc, Montreal

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY